SUPN News and Press, Supernus Pharmaceuticals Inc. From 01/06/21

ROCKVILLE, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present...

It has been eight months since we last looked in on a promising biopharma concern named Supernus Pharmaceuticals. Some significant news has posted since then including some recently disclosed encouraging study news. We update our investment thesis on Supernus in the paragraphs bel...

Shares of Supernus Pharmaceuticals (NASDAQ: SUPN) are up by 16.7% as of 2:18 p.m. EST on Wednesday after rising by as much as 22.4% earlier today. Investors are bidding up shares of the biopharmaceutical company following its release of positive results from a phase 3 clinical trial...

Lizhi (LIZI) +29%.Ekso Bionics Holdings (EKSO) +25%.AgEagle Aerial Systems (UAVS) +22%.ENGlobal Corporation (ENG) +23%.Supernus Pharmaceuticals (SUPN) +23%.Scopus BioPharma (SCPS) +21%.Mogo (MOGO) +18%.Magnite (MGNI) +18%.Kopin Corporation (KOPN) +18%.Magna International (MGA) +18%.InMed Phar...

Met primary endpoint with robust statistical significance Showed efficacy on both hyperactivity/impulsivity and inattention subscales with statistical significance Showed statistically significant onset of action as early as week 2 Had a...

ROCKVILLE, Md., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will partici...

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. A list of cheap stocks. For further details see: XLV: Healthcare Dashboard For November

ROCKVILLE, Md., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present...

Gainers: [[XPER]] +27.4%. [[FLGT]] +16.7%. [[AHT]] +16.3%. [[GTHX]] +13.9%. [[SCOR]] +11.4%.Losers: [[SUPN]] -22.9%. [[BYND]] -22.4%. [[ARNA]] -17.8%. [[NEX]] -15.6%. [[YALA]] -13.4%. For further details see: XPER, SUPN, AHT and ARNA among after-hours movers

Supernus Pharmaceuticals (SUPN) says it received a complete response letter regarding its new drug application for SPN-812 for the treatment of ADHD in pediatric patients 6-17 years old.The FDA says the application is not ready for approval in its present form, citing Superna's in-house labor...